Bavarian Nordic still hopes to find financing for Covid-19 vaccine

In spite of positive preclinical data, Bavarian Nordic maintains that the firm itself will not finance further studies after the first phase I/II study. The company remains optimistic, however, about the prospects of finding capital for the vaccine from external sources.

Photo: Bavarian Nordic / PR

While Bavarian Nordic's vaccine candidate against Covid-19 will soon enter into the first in-human phase I/II study, the Danish vaccine company is on the lookout for a partner to finance its further development and the process of taking the Covid-19 vaccine to market.

"We need financing, but we're optimistic. We hope the capital will turn up, and all along we've said that in order to get some financing on the table we need good data," Bavarian Nordic Vice President of Investor Relations and Communications Rolf Sass Sørensen tells Ritzau Finans.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs